Phase I study of bevacizumab and sorafenib combined with low dose cyclophosphamide in patients with refractory solid tumors and leukemia.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
Indications Bone cancer; Leukaemia; Lymphoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions

20 Apr 2020 Results (N=24), subgroup analysis of an expansion cohort assessing tolerability and drug activity patients with refractory or recurrent solid tumors, published in the European Journal of Cancer
27 Aug 2019 Results assessing population pharmacokinetic modeling by using data from two studies (RELHEM and ANGIO1) published in the Clinical Cancer Research.
07 Jun 2016 Results from an expansion part of this trial (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com